Intensive blood pressure (BP) and glucose control are still regarded as the cornerstones of CKD prevention, together with prognostic and renoprotective medication, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose co-transporter-2 inhibitors (SGLT2i), and renin-angiotensin-aldosterone system (RAAS) blocking therapy [13, 16]. The gene discussed is GLP1R; the disease is chronic kidney disease.